Trial Profile
A Phase IIIb/IV, Multinational, Multicentre, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 1 Diabetes Mellitus/ "HALT" Sub-study: Multicentre, Open Clinical Trial to Assess the Effect of Insulin Glargine on Symptomatic Hypoglycaemia, Fear of Hypoglycaemia and Quality of Life in Patients With Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms AT.LANTUS; HALT
- Sponsors Sanofi
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 20 Jul 2018 New trial record
- 26 Jun 2018 Results comparing data from TAKE-CONTROL, AT.LANTUS, and ATLAS Studies presented at the 78th Annual Scientific Sessions of the American Diabetes Association